In the phase 3 PRESTO trial, men with high-risk biochemically recurrent prostate cancer received intensified ADT with apalutamide, with or without abiraterone plus prednisone, for 1 year.
In the phase 3 PRESTO trial, men with high-risk biochemically recurrent prostate cancer received intensified ADT with apalutamide, with or without abiraterone plus prednisone, for 1 year.
For patients with metastatic castration-resistant prostate cancer, talazoparib combined with enzalutamide achieved better progression-free survival than enzalutamide alone.
In patients with advanced clear cell renal cell carcinoma, an optimal sitravatinib dose combined with a fixed dose of nivolumab improved outcomes in a phase 1-2 trial.
Researchers involved in a large cohort study from three major institutions are calling for broader use of trimodal therapy for muscle-invasive bladder cancer.